Search

Quercus acutissima whole

Quercus acutissima whole is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

Bisphosphocin Nu-3

Bisphosphocin Nu-3 is under investigation in clinical trial NCT02737722 (Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus).

Isoflavone

Soybean is an exceptionally rich source of dietary isoflavones, where the average isoflavone content is 1-2 mg/gram [A33103]. … Isoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation.

Sepiapterin

[L53548,L53593] Sepiapterin was granted marketing authorization by the European Commission in June 2025 and by the US FDA in July 2025 for the treatment of adults and children with phenylketonuria. … Sepiapterin is a small molecule activator of phenylalanine hydroxylase (PAH) used to reduce phenyalanine levels in patients with phenylketonuria.

Xanthan gum

It is used as a thickening agent and stabilizer in emulsions. … The major constituents include D-glucose, D-mannose, and D-glucuronic acid. Xanthan gum is a direct food additive permitted for direct addition to food for human consumption by the FDA.

Phenolsulfonphthalein

Phenolsulfonphthalein is being investigated for use clinically due to its weak estrogen mimicking actions [A174964]. … Phenolsulfonphthalein or otherwise called phenol red is a pH indicator commonly used in cell biology laboratories.

Prostaglandin D2

The principal cyclooxygenase metabolite of arachidonic acid. It is released upon activation of mast cells and is also synthesized by alveolar macrophages. Among its many biological actions, the most important are its bronchoconstrictor, ...

Plinabulin

Ribociclib

Ribociclib was approved by the FDA in March 2017 under the brand name Kisqali.

Anifrolumab

[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.